Value Based Medicine News Today

Racial disparities in end-of-life care, the role of wellness and faith in minority health, award-winning research on health disparities, societal factors impacting cardiometabolic health, and rising mental health challenges among US youth are all covered this week in the Center on Health Equity and Access.

Yael Mauer, MD, MPH, discusses the patient population who benefits most from interventions with glucagon-like peptide-1 (GLP-1) therapies and explores the underlying mechanisms at work.

Diana Isaacs, PharmD, chair of a recent Institute for Value-Based Medicine® event hosted in conjunction with Cleveland Clinic, details the up-and-coming therapies impacting the scope of treatment in diabetes, obesity, and cardiometabolic health, as well as their associated challenges.

Robert Zimmerman, MD, discussed the adverse side effects associated with glucagon-like peptide-1 (GLP1) and multi-agonist therapies, as well as explored the challenges in developing these interventions.

Laife Reply, a company within the Reply Group focused on using AI, Big Data and Machine Learning to innovate preventive healthcare and treatment processes has developed, in collaboration with IEO ,...

Coverage from the Institute for Value-Based Medicine event in Tampa, Florida, with Moffitt Cancer Center.

Coverage from the Institute for Value-Based Medicine event with the University of Kansas Cancer Center in Kansas City, Kansas.

Expert interviews highlight advancements and challenges in diabetes care technology, including automated insulin delivery systems and continuous glucose monitors, as well as improvements in insurance coverage.

At an Institute for Value-Based Medicine® event held in Phoenix, Arizona, experts from Banner Health and Aetna discussed how health inequities and social determinants of health can affect primary care in patients with any type of insurance.

Sandra Stein, MD, of Banner Health Plans, details how she provides clinical and medical leadership in her role as chief medical officer.